Avexitide Hits Phase 3 Primary Endpoint with 55% Reduction in Hypoglycemic Events

summarizeSummary

Positive Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia were announced, meeting the primary endpoint with a 55% reduction in hypoglycemic events and all secondary endpoints. NDA submission is planned by end of 2026.

check_boxKey Events · Product Development and Regulatory · AMLX

• Phase 3 Primary Endpoint Met

  The LUCIDITY trial met its FDA-agreed primary endpoint: avexitide demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003).

• All Secondary Endpoints Met

  Statistically significant reductions were seen in Level 2 hypoglycemic events by SMBG, Level 2 by CGM, and independently adjudicated Level 3 events.

• Favorable Safety Profile

  Avexitide was generally well-tolerated with no serious adverse events related to treatment. Most common adverse events were diarrhea, injection site erythema, and injection site bruising.

• NDA Submission by End of 2026

  Amylyx plans to submit a New Drug Application to the FDA by the end of 2026. Avexitide has Breakthrough Therapy and Orphan Drug Designations.

auto_awesomeAnalysis · AMLX · Life Sciences

The Phase 3 LUCIDITY trial met its primary endpoint with a 55% reduction in Level 2 and Level 3 hypoglycemic events (p=0.000003) and all secondary endpoints. This is the first positive pivotal data for a potential first-in-class treatment for post-bariatric hypoglycemia, a condition with no FDA-approved therapies. The company plans to submit an NDA by end of 2026, with potential commercialization in 2027. The stock is trading near its 52-week high, reflecting high expectations, and this data validates the investment thesis.